CYP2C19 is one of the most important drug-metabolizing enzymes in the liver, responsible for processing a wide range of medications including anticoagulants, proton pump inhibitors, antidepressants, and antifungals. While much attention focuses on the well-characterized loss-of-function variants (*2, *3) and the gain-of-function *17 allele, rs3814637 is a separate upstream regulatory variant located approximately 1,400 bases before the CYP2C19 transcription start site. Carriers of the T allele show altered CYP2C19-mediated drug metabolism, with the most robust evidence coming from warfarin dosing studies.

The Mechanism

Rs3814637 sits in the regulatory region upstream of CYP2C19¹¹ Located ~1,374–1,393 bp upstream of the CYP2C19 transcription start site per Ensembl VEP and is classified as an upstream gene variant. The precise molecular mechanism by which the T allele alters CYP2C19 activity has not been fully characterized in published literature, but the pharmacokinetic data consistently show that T-allele carriers have higher plasma concentrations of CYP2C19 substrates, suggesting either reduced enzyme activity or expression. Unlike the *2 allele's splice-site mutation, rs3814637 likely exerts its effect through altered transcription factor binding or promoter-region regulation.

Warfarin exists as two enantiomers²² Mirror-image forms of the same molecule with different metabolic fates: S-warfarin (more potent, metabolized mainly by CYP2C9) and R-warfarin (metabolized predominantly by CYP1A2, CYP3A4, and CYP2C19). The rs3814637 variant specifically affects R-warfarin clearance, meaning T-allele carriers clear this enantiomer more slowly, raising the effective anticoagulant exposure.

The Evidence

The strongest evidence for rs3814637 comes from a 2022 meta-analysis by Wang et al.³³ 2022 meta-analysis by Wang et al.
Wang D et al. Impact of CYP2C19 gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis. Pharmacogenomics, 2022 analyzing nine studies totaling 1,393 patients. Individuals with the TT genotype required 34% lower warfarin maintenance doses than CC carriers; CT heterozygotes required 18% less. A companion pharmacokinetic study by Lane et al. (2012)⁴⁴ Lane et al. (2012)
Lane S et al. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol, 2012 independently identified rs3814637 as one of the key genetic determinants of R-warfarin clearance in a long-term anticoagulation cohort.

For other CYP2C19 substrates, a Chinese lung-cancer study by Tan et al. (2022)⁵⁵ Tan et al. (2022)
Tan T et al. Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer. Front Pharmacol, 2022 found that TT+CT carriers showed significantly higher peak plasma concentrations of anlotinib — a multikinase inhibitor — and elevated rates of hypertension and hemoptysis compared to CC carriers. This is consistent with a broader pattern of reduced CYP2C19-mediated clearance in T-allele carriers.

Practical Actions

The most direct clinical implication is for warfarin dosing. Anyone prescribed warfarin who carries the T allele — particularly TT homozygotes — may need a lower starting dose and closer INR monitoring during initiation. The effect is modest for heterozygotes (CT, ~18% dose reduction) but more pronounced for homozygotes (TT, ~34% reduction). Standard warfarin dosing algorithms do not currently include rs3814637, so this information is supplementary to — not a replacement for — clinical INR monitoring and algorithmic dosing (e.g., IWPC or WarfarinDosing.org algorithms that already incorporate CYP2C9 and VKORC1).

The T allele is enriched in East Asian populations (15–17% in Japanese cohorts) compared to Europeans (~6%), which may partly explain observed population differences in warfarin sensitivity.

Interactions

Rs3814637 acts independently of the major CYP2C19 star alleles (*2 via rs4244285 and *17 via rs12248560). A person carrying both rs3814637 T and the *2 no-function allele (rs4244285 A) would have compounded reductions in CYP2C19-mediated warfarin metabolism. Conversely, carrying rs3814637 T alongside *17 (rs12248560 T) creates opposing effects in the CYP2C19 locus and could complicate pharmacokinetic prediction. The *2 and *17 alleles are already captured by separate GeneOps entries; this entry reflects the independent additive contribution of rs3814637.

Glucose-6-phosphate dehydrogenase (G6PD) is a housekeeping enzyme present in every cell, but it is most critically important in red blood cells — which have no mitochondria and therefore depend entirely on G6PD as their sole source of NADPH¹¹ NADPH
Nicotinamide adenine dinucleotide phosphate (reduced form) — a cellular reducing agent essential for regenerating glutathione and neutralizing oxidative stress. When G6PD activity is severely reduced, oxidative stress from certain drugs, foods, or infections overwhelms the red cell's antioxidant defenses, causing the cell membrane to rupture — a process called acute hemolytic anemia²² acute hemolytic anemia
Sudden, triggered destruction of red blood cells causing jaundice, dark urine, fatigue, and anemia that can require blood transfusion.

The rs5030868 A allele creates the G6PD Mediterranean variant — a missense change (c.563C>T on the coding strand) that substitutes serine with phenylalanine at position 188 of the mature protein (p.Ser188Phe, MANE Select transcript). This substitution disrupts a dimer interface contact residue, severely destabilizing the active enzyme structure and reducing G6PD activity to less than 10% of normal — classified by the WHO as Class II severe deficiency³³ Class II severe deficiency
Class II variants retain 1–10% of normal enzyme activity and cause acute hemolytic crises under oxidative challenge; Class I (most severe) causes chronic hemolysis even at rest. G6PD deficiency is the most common human enzymopathy, affecting more than 400 million people worldwide⁴⁴ affecting more than 400 million people worldwide
Cappellini & Fiorelli, Lancet 2008; geographic distribution mirrors historic malaria endemicity, and the Mediterranean variant is the predominant severe form across the Mediterranean basin, Middle East, and South Asia, where allele frequencies reach 1–10% in some sub-populations.

The Mechanism

G6PD catalyzes the first and rate-limiting step of the pentose phosphate pathway: converting glucose-6-phosphate to 6-phosphogluconate while reducing NADP⁺ to NADPH. In red blood cells, this NADPH is the only means of regenerating reduced glutathione, the cell's primary intracellular antioxidant. When NADPH falls below a critical threshold — triggered by oxidative challenge from drugs, fava bean ingestion (which liberates vicine and convicine, potent pyrimidine glycoside oxidants), or febrile infection — unprotected hemoglobin is oxidized, forms Heinz bodies⁵⁵ Heinz bodies
Precipitates of denatured hemoglobin that attach to the red cell membrane and trigger rapid removal by the spleen, and the red cell is destroyed.

The Ser188Phe substitution places a bulky aromatic phenylalanine residue at a dimer interface contact point, severely disrupting the quaternary structure on which G6PD catalytic activity depends. Mason et al. 2007⁶⁶ Mason et al. 2007
Blood Reviews; review of 160 G6PD mutations; severe variants predominantly destabilize dimer interface or structural NADP-binding residues identify this class of structural disruptions as responsible for the near-complete loss of enzyme activity in Class II variants. At <10% residual activity, the Mediterranean variant provides insufficient NADPH buffering capacity even under moderate oxidative challenge — lower than the Class III variants common in Africa (~10–60% residual), and substantially more dangerous in terms of hemolytic threshold.

Because the G6PD gene is on the X chromosome, the variant is X-linked: males carrying the A allele are hemizygous and express the full severe deficiency phenotype. Females with one A copy are carriers and may have partial-to-full deficiency depending on X-chromosome inactivation⁷⁷ X-chromosome inactivation
Random silencing of one X chromosome per cell; if the wild-type allele is preferentially silenced (skewed inactivation), a heterozygous female can have enzyme activity as low as a hemizygous male.

The Evidence

ClinVar VCV000100057⁸⁸ VCV000100057 classifies this variant as Pathogenic/Likely pathogenic based on 63 submissions (48 pathogenic with multiple submitters, no conflicts) — the highest evidence tier. Conditions include nonspherocytic hemolytic anemia due to G6PD deficiency, favism (fava-bean triggered hemolysis), malaria susceptibility, and neonatal hyperbilirubinemia.

A critical and underappreciated clinical consequence of G6PD deficiency is its interference with HbA1c measurements. Because G6PD-deficient red cells have shorter lifespans, hemoglobin accumulates less glycation, producing systematically lower HbA1c readings despite normal or elevated blood glucose. Breeyear et al. 2024 (Nature Medicine)⁹⁹ Breeyear et al. 2024 (Nature Medicine)
Adaptive selection at G6PD and disparities in diabetes complications; 42 institutions across the US found that G6PD deficiency masked pre-diabetic hyperglycemia in the years before clinical diabetes diagnosis, and estimated that 12% of diabetic retinopathy cases and 9% of neuropathy cases in African ancestry participants of the ACCORD trial were attributable to underdiagnosed/undertreated hyperglycemia caused by suppressed HbA1c readings. A case report by Danzig et al. 2011¹⁰¹⁰ A case report by Danzig et al. 2011
Adolescent with G6PD deficiency and type 1 diabetes; HbA1c consistently discordant with blood glucose measurements; hemolysis reduced red cell lifespan and glycated hemoglobin accumulation further illustrates this diagnostic pitfall in an individual patient.

Regarding drug safety, Youngster et al. 2010¹¹¹¹ Youngster et al. 2010
Drug Safety systematic review of MEDLINE, PubMed, Cochrane; evidence-based review of hemolysis-inducing drugs in G6PD-deficient patients identified seven drugs with solid evidence for prohibition: primaquine, dapsone, rasburicase, nitrofurantoin, methylene blue, phenazopyridine, and toluidine blue. The risk is particularly severe for Class II variants like G6PD Mediterranean because the minimal residual enzyme activity provides almost no buffer against oxidative drug stress.

Practical Actions

The primary goal for carriers of the G6PD Mediterranean variant is identifying and avoiding oxidative triggers before an acute crisis occurs. Seven drugs have solid evidence for hemolysis induction in G6PD-deficient patients and must be flagged with prescribing physicians before any new prescription. Fava beans (broad beans, Vicia faba) and their pollen must also be completely avoided. When an acute hemolytic episode occurs — sudden pallor, jaundice, dark or tea-colored urine — immediate medical evaluation is required; severe Class II crises can require blood transfusion.

For diabetes screening, carriers should request fasting plasma glucose (FPG) or a 2-hour oral glucose tolerance test (OGTT) as the primary screening method rather than relying on HbA1c alone, which will read artificially low. If HbA1c is the only test available, treat any value above 5.5% with heightened concern and correlate with self-monitored blood glucose values.

Interactions

rs5030868 (G6PD Mediterranean) can co-occur with rs2230037 (G6PD c.376A>G, p.Asn126Asp) on the same chromosome, forming a compound allele with further reduced enzyme activity. Individuals carrying rs5030868 should ideally have rs2230037 assessed to determine whether the compound allele is present, as this would shift management toward even greater vigilance and neonatal jaundice screening planning.

The HbA1c interference from G6PD deficiency interacts critically with diabetes screening protocols relying exclusively on HbA1c. Concurrent hemoglobinopathies (e.g., sickle cell trait, thalassemia) — which co-segregate with G6PD Mediterranean in overlapping populations — further complicate HbA1c reliability and compound the diagnostic challenge.

Your hormones don't act directly on cells — they bind to receptors that activate relay proteins called heterotrimeric G proteins. The G-protein beta-3 subunit (GNB3) is one of these essential relay molecules, present in virtually every cell in your body. The C825T polymorphism (rs5443) at exon 10 of the GNB3 gene¹¹ The C825T polymorphism (rs5443) at exon 10 of the GNB3 gene
A synonymous C-to-T change that does not alter the amino acid sequence but dramatically changes how the mRNA is processed triggers alternative splicing that removes 41 amino acids from the protein — creating a shortened, more constitutively active variant called Gβ3-s. The result is a signaling amplifier: every hormone, neurotransmitter, and growth factor that acts through a G-protein-coupled receptor (GPCR) gets a louder response in T-allele carriers.

This makes GNB3 C825T one of the most pleiotropic common variants ever described. The same molecular change raises blood pressure, shifts body weight set-points, alters how well antidepressants work, and even modulates sleep timing — because all of these systems rely on GPCR signaling through the very subunit this variant modifies.

The Mechanism

In a normal heterotrimeric G protein, the alpha, beta, and gamma subunits dissociate upon receptor activation to trigger downstream cascades. The T allele of rs5443 causes deletion of nucleotides 498–620 of exon 9 during mRNA splicing²² The T allele of rs5443 causes deletion of nucleotides 498–620 of exon 9 during mRNA splicing
The variant lies in exon 10 but acts as a splicing enhancer element that disrupts exon 9 recognition, producing the Gβ3-s protein lacking 41 amino acids and one WD-repeat domain.

The mechanistic picture is more nuanced than the original "gain-of-function" framing suggested. Biochemical studies show Gβ3-s cannot form stable complexes with Gγ or Gα subunits³³ Biochemical studies show Gβ3-s cannot form stable complexes with Gγ or Gα subunits
Smrcka and Sternweis established that Gβγ dimerization requires the WD-repeat domain that Gβ3-s has lost, and the protein cannot localize to the plasma membrane normally. A more recent model proposes the mechanism runs through GRK2 regulation: wild-type Gβ3 assembles an E3 ubiquitin ligase (DDB1-CUL4A-ROC1) that targets GRK2 for ubiquitination and degradation. The Gβ3-s splice variant disrupts this Gβ3-DDB1 binding⁴⁴ The Gβ3-s splice variant disrupts this Gβ3-DDB1 binding
Without ubiquitination, GRK2 accumulates and blunts receptor desensitization, sustaining signaling. The net cellular result — enhanced, prolonged GPCR signal throughput — is well-replicated even if the precise molecular mechanism remains under investigation.

In vascular smooth muscle cells this leads to heightened Na⁺/H⁺ exchanger activity, sodium retention, and cell proliferation⁵⁵ heightened Na⁺/H⁺ exchanger activity, sodium retention, and cell proliferation
Known mechanisms linking G-protein over-activation to hypertension. In adipocytes, augmented Gi signaling reduces cAMP-mediated lipolysis, shifting fat storage balance. In serotonin and norepinephrine receptor pathways, sustained signaling alters mood regulation — which is where antidepressant pharmacogenetics comes in.

The Evidence

The original discovery by [Siffert et al. (1998) | Nature Genetics 1998; PMID 9545495] found the T allele at a frequency of 53% in hypertensives versus 44% in normotensives, and showed that lymphocytes carrying the T allele had 2–4-fold enhanced responses to Gi-coupled stimulation. Subsequent research has extended across multiple phenotypes.

Blood pressure and cardiovascular risk: [A meta-analysis of 34 studies including 14,094 hypertensive cases and 17,760 controls | Siffert group meta-analysis, J Hypertens 2007; PMID 17278960] found carriers of two T alleles (TT genotype) had OR 1.08 (95% CI 1.01–1.15) for hypertension, and TT+CT carriers combined had OR 1.17 (95% CI 1.06–1.29) versus CC. In a [cohort of 932 middle-aged Austrians | Zweier et al. Arterioscler Thromb Vasc Biol 2003; PMID 12624279], T allele carriers showed 60% higher odds of advanced carotid plaques (OR 1.61, 95% CI 1.00–2.58) and significantly lower insulin sensitivity in abdominally obese men (~9% reduction, P=0.012).

Antidepressant response: [A 2014 meta-analysis | Li et al. Prog Neuropsychopharmacol Biol Psychiatry; PMID 25451402] found the T allele (both allele and dominant models) was significantly associated with better antidepressant response in major depressive disorder, with the association strongest in Asian populations and absent in Caucasians. An independent study of [166 unipolar depression patients | Arias et al. 2007; PMID 17460549] showed the GNB3 T allele was significantly associated with antidepressant response after 2nd-line treatment (remission OR 0.18, P=0.02 for lack of remission with T allele — meaning T allele carriers were much more likely to achieve remission).

Sleep and circadian timing: [A sleep study | Parsons et al. J Sleep Res 2014; PMID 24635757] found a significant association between GNB3 rs5443 and global Pittsburgh Sleep Quality Index scores (recessive model, P=0.005), and combined analysis across cohorts linked the T allele to a mild preference for morningness. G-protein signaling in the suprachiasmatic nucleus modulates circadian pacemaking, providing a plausible mechanistic link.

Obesity and metabolic syndrome: Results are population-dependent. Meta-analyses suggest TT homozygotes have modestly elevated obesity risk in some populations, and T allele carriers responding better to non-pharmacological weight loss programs — while the CC genotype benefits more from pharmacological intervention (sibutramine, now withdrawn). Taiwanese and some East Asian cohorts show null or reversed associations for BMI, indicating strong gene-environment interaction: the T allele's metabolic effects appear most pronounced in obesogenic environments.

Practical Implications

For those with the CT or TT genotype and elevated blood pressure, standard dietary sodium restriction (targeting under 2,000 mg/day) may be especially effective given the enhanced Na⁺/H⁺ exchange activity linked to this variant. Potassium-rich foods (legumes, leafy greens, avocado) can offset sodium's vasopressor effects. If blood pressure remains uncontrolled, this variant may inform pharmacogenetic selection — beta-blockers and certain G-protein-modulating antihypertensives have shown differential efficacy by genotype.

For those with depression and the T allele, the antidepressant evidence (while mixed by ethnicity) suggests there is no pharmacogenetic reason to avoid standard first-line treatment; if anything, T-allele carriers may respond relatively well to antidepressants in some populations. Discuss your complete pharmacogenomic profile with a prescriber before making treatment decisions.

For CC homozygotes: a counterintuitive finding is that the wild-type CC genotype may carry higher metabolic risk in non-obese contexts (elevated triglycerides and cholesterol in normal- weight Taiwanese subjects) and responds less well to behavioral weight-loss interventions alone.

Interactions

GNB3 rs5443 has been examined in interaction with serotonin pathway genes in depression. [A study of antidepressant response | PMID 19560507] found a significant gene-gene interaction between GNB3 (rs5443) and HTR2A (rs6311, the serotonin 2A receptor promoter variant), as well as a 3-locus model involving GNB3 × HTR2A × SLC6A4. Since G-protein beta subunits serve downstream of serotonin receptors (5-HT1A, 5-HT2A, and others are GPCRs), functional differences in both the receptor and the G-protein effector could combine to alter signaling magnitude in an epistatic fashion.

A [Korean diurnal preference study | PMID 27660894] found a synergistic interaction among the GNB3 C/T SNP (rs5443), the ARNTL C/T SNP, and a PER2 G/A SNP on the risk of eveningness preference — suggesting GNB3-mediated signaling interacts with core clock components to shape circadian phenotype.

Compound implication for GNB3 rs5443 (CT or TT) + HTR2A rs6311 (CC or CT): Carriers of both the GNB3 T allele and the HTR2A T102C variant may have a combined effect on serotonergic G-protein signal transduction that influences antidepressant response beyond what either variant predicts alone. If considering antidepressant pharmacogenomics, both variants are worth discussing with a clinician familiar with psychiatric pharmacogenetics.

Hepatic lipase (HL), encoded by the LIPC gene on chromosome 15, is the enzyme that finishes the job of remodeling lipoprotein particles at the liver surface. After lipoprotein lipase strips triglycerides from VLDL particles in peripheral tissues, the remnants — and the large HDL2 particles that have absorbed cholesterol from arterial walls — arrive at the liver. HL then hydrolyzes their remaining triglycerides and phospholipids, converting HDL2 into the smaller, denser HDL3 particles that are primed for another round of reverse cholesterol transport.

rs8034802 is an intronic variant in LIPC. Unlike the well-characterized promoter variants rs1532085, rs1800588 (-514C>T), and rs2070895 (-250G>A) — which sit in transcription factor binding sites and directly reduce LIPC expression — rs8034802's functional mechanism is not yet fully characterized. What is documented is its association with the same downstream phenotype: higher baseline HDL-C in A allele carriers, alongside a meaningful interaction with lifestyle modification.

The Mechanism

The A allele at rs8034802 is in the same directional pathway as the known LIPC eQTL variants: carriers show elevated total HDL-C, which reflects slowed remodeling of HDL2 into HDL3 rather than increased production of transport-active HDL. When HL activity is reduced, large HDL2 particles accumulate in circulation. This raises the number reported on a standard HDL-C test while the functional capacity of those particles — their efficiency at extracting cholesterol from arterial walls and delivering it to the liver — may not increase proportionally.

The triglyceride side is the other half of the picture. HL also clears triglyceride-rich remnant particles; reduced HL activity allows these to persist longer in circulation, elevating fasting triglycerides. The resulting phenotype — elevated HDL-C alongside elevated triglycerides — is a recognized pattern at the LIPC locus.

The Evidence

The primary evidence for rs8034802 specifically comes from the Look AHEAD study¹¹ Look AHEAD study
Huggins et al. Do genetic modifiers of HDL-C and TG levels also modify their response to a lifestyle intervention in obesity and T2DM? Circ Cardiovasc Genet, 2013, which evaluated 82 SNPs across 31 lipid loci in 3,561 participants with obesity and type 2 diabetes who were randomized to intensive lifestyle intervention (ILI) versus usual diabetes care. Among the GWAS-identified lipid variants studied, rs8034802 was one of only two (alongside CETP rs3764261) associated with both higher baseline HDL-C and a nominally significant HDL-C increase specifically in the ILI group (P=0.013; treatment interaction P=0.046). The variant also showed associations with triglyceride changes during intervention (P<0.05). This makes rs8034802 notable not just as a baseline HDL-C modifier, but as a gene-environment interaction variant where the lifestyle context amplifies the effect.

The broader LIPC literature — including a meta-analysis of 87 studies (101,988 participants)²² meta-analysis of 87 studies (101,988 participants)
Liao et al. The cross-sectional study of hepatic lipase SNPs and plasma lipid levels. Medicine, 2020 — consistently shows that LIPC variants reducing HL activity raise HDL-C while simultaneously elevating triglycerides, LDL, and total cholesterol. A Brazilian cohort study³³ Brazilian cohort study
de Lima et al. LIPC -250A/G variant enhances carotid atherosclerosis. Atherosclerosis, 2020 found that LIPC variants with reduced HL activity paradoxically increased carotid atherosclerosis risk despite higher HDL-C — because the elevated HDL-C comes from accumulation of triglyceride-rich, cholesteryl ester-depleted HDL2 particles with impaired reverse cholesterol transport function.

Evidence for this specific rs8034802 variant is emerging — the Look AHEAD finding is a single large study. The broader LIPC locus has strong evidence, but rs8034802 specifically has not been replicated independently.

Practical Actions

For TT homozygotes (most common in Europeans, ~44% globally), hepatic lipase activity is at the reference level for this variant. Your HDL-C and triglycerides are not influenced by this locus.

For AT heterozygotes (~45% globally), the A allele confers moderately elevated baseline HDL-C. If you have obesity or type 2 diabetes, the Look AHEAD data suggest you may see above-average HDL-C gains from an intensive lifestyle intervention — making it particularly worthwhile to pursue. At the same time, the LIPC pattern of simultaneous HDL-C and triglyceride elevation means fasting triglycerides deserve as much attention as the HDL-C number on your lipid panel.

For AA homozygotes (~11% globally, up to 40% in East Asian populations), the dual elevation of HDL-C and triglycerides is most pronounced. The HDL-C reading may look encouraging on a standard panel, but asking your physician for apolipoprotein A-I (apoA-I) and fasting triglycerides gives a more complete picture of whether your HDL is genuinely protective. The HDL advantage is most preserved when saturated fat intake is limited and omega-3 polyunsaturated fats are emphasized.

Interactions

rs8034802 is located in the same LIPC gene as rs1532085 — the GWAS lead SNP for the LIPC locus (P=9.7×10⁻³⁶ in >100,000 Europeans). If your genetic test reports both variants, rs1532085 has much stronger population-level evidence for hepatic lipase regulation. rs8034802 adds the gene-lifestyle interaction dimension that rs1532085 studies have not specifically characterized.

CETP variants (rs3764261 and rs708272) were co-identified in the Look AHEAD study as the other major lifestyle-modifiable lipid locus. Combined high-HDL genotypes at both CETP and LIPC may amplify the HDL-C response to lifestyle intervention, though the cardiovascular benefit depends on whether the elevated HDL is functionally active (CETP mechanism) or large-particle accumulation (LIPC mechanism).

Adiponectin is one of the body's most protective metabolic hormones — secreted exclusively by fat cells, it simultaneously suppresses hepatic glucose output, activates AMPK in skeletal muscle, and shields artery walls from inflammation. People with high circulating adiponectin have meaningfully lower rates of type 2 diabetes, coronary artery disease, and ischemic stroke. rs822391 is an intronic C-to-T substitution in the first intron of ADIPOQ¹¹ ADIPOQ
The gene encoding adiponectin (also called APM1 or Acrp30), located at chromosome 3q27 — a locus strongly and repeatedly confirmed as the primary genetic determinant of circulating adiponectin levels in population studies, sitting 407 nucleotides into intron 1 at GRCh38 position chr3:186,846,014. The C allele (the minor allele, at roughly 20% frequency in Europeans and only 4% in Africans) has been associated with ischemic stroke risk and is implicated in modulation of adiponectin output at the 3q27 locus.

The Mechanism

Intronic variants in ADIPOQ influence adiponectin levels through several possible mechanisms: disruption of intronic enhancer elements²² intronic enhancer elements
Regulatory sequences within introns that recruit transcription factors to boost gene expression from a distance; intron 1 of ADIPOQ contains multiple such elements active in adipocytes, alterations in pre-mRNA splicing³³ pre-mRNA splicing
The process removing introns from precursor RNA; variants within the first few hundred nucleotides of an intron can affect splice site recognition and exon inclusion rates even without changing the consensus AG/GT dinucleotides, or tagging of nearby functional variants through linkage disequilibrium⁴⁴ linkage disequilibrium
The tendency for nearby genetic variants to be inherited together as a haplotype; rs822391 sits in the same ADIPOQ locus LD block as known functional variants including rs2241766 (T45G) and rs1501299 (+276G>T). The rs822391 C allele is the minor allele globally, with strong population stratification: frequency of roughly 20% in Europeans and South Asians, 10% in East Asians, and as low as 4% in African populations — a pattern consistent with population-specific selection acting on the ADIPOQ locus. The GTEx database identifies this variant as an eQTL for ADIPOQ-AS1 in testis tissue (NES −0.23, p=1.6×10⁻⁹), and the T allele shows positive regulatory effects in arterial tissue (NES +0.21, p=4.2×10⁻⁵), suggesting allele-specific effects on ADIPOQ-neighborhood gene regulation.

The Evidence

The most direct clinical evidence for rs822391 comes from a Korean case-control study by Cheong et al. (2011)⁵⁵ Cheong et al. (2011)
Six ADIPOQ polymorphisms were genotyped in a stroke vs. control cohort; rs822391 was among those showing significant association in both dominant and additive logistic regression models after adjustment for age and sex, which reported that the C allele (described in that paper as the T>C substitution, confirming C as the risk direction on the plus strand) was significantly associated with ischemic stroke risk (p<0.05). This is biologically coherent: adiponectin is an established anti-atherosclerotic and anti-thrombotic hormone, and variants that reduce its circulating levels — including rs822391 C allele carriers — face downstream consequences in cerebrovascular protection.

At the broader locus level, Heid et al. (2010)⁶⁶ Heid et al. (2010)
Genome-wide association analyses of 4,659 Europeans followed by replication in 13,795 additional subjects, n=18,454 total, identifying ADIPOQ as the dominant genetic determinant of plasma adiponectin established that the ADIPOQ 3q27 region explains approximately 6.7% of variance in circulating adiponectin levels in Europeans — the single largest genetic contributor to this phenotype. rs822391 lies within this locus, and the Jackson Heart Study (n>5,000 African Americans) included it among a panel of ADIPOQ variants examined for adiponectin associations with gender-specific effects, finding locus-wide signals concentrated in several correlated variants including rs16861205, a close neighbor at chr3:186,843,845.

On the intervention side, Sepidarkish et al. (2022)⁷⁷ Sepidarkish et al. (2022)
Systematic review and meta-analysis of 43 randomized controlled trials, n=3,434 participants across diverse populations demonstrated that omega-3 fatty acid supplementation raises circulating adiponectin with a pooled effect size of SMD 0.21 (95% CI 0.04–0.37, p=0.01), with the strongest effects at doses exceeding 2,000 mg EPA/DHA per day for more than 10 weeks. This intervention-level evidence directly informs the management of C allele carriers whose baseline adiponectin is already genetically suppressed.

Practical Actions

Carriers of the C allele cannot override the intronic regulatory change, but circulating adiponectin is modifiable through targeted nutrition. Long-chain omega-3 fatty acids (EPA and DHA) are the best-supported dietary upregulators of adiponectin, acting through PPAR-alpha activation in adipocytes to increase ADIPOQ transcription — a mechanism that partially compensates for genetically lower baseline secretion. Saturated fatty acids specifically suppress ADIPOQ promoter activity through competitive PPAR-gamma antagonism, so replacing saturated fat with mono- and polyunsaturated sources measurably raises adiponectin independent of total caloric intake.

Given the documented association with stroke risk, C allele carriers — particularly CT and CC individuals — benefit from monitoring the biomarkers that reflect the downstream consequences of lower adiponectin: fasting serum adiponectin, fasting insulin, and blood pressure. Early detection of hypoadiponectinemia (below 5 µg/mL) or elevated fasting insulin (above 8 µIU/mL) allows targeted intervention before vascular consequences develop.

Interactions

rs822391 lies within the same ADIPOQ intron 1 locus block as rs16861194 (−11426A>G upstream promoter), rs16861205 (intron 1 A>G), and nearby rs1501299 (+276G>T, intron 2). Individuals carrying risk alleles at multiple ADIPOQ locus variants — which tend to cluster in the same low-adiponectin haplotype — show substantially greater reductions in circulating adiponectin than any single variant predicts. The compounding of rs822391 C allele with rs2241767 G or rs1501299 T creates a high-priority metabolic target where direct adiponectin measurement is especially warranted. See related SNPs for individual variant profiles.

Your skin is a living wall, held together by a precisely timed demolition system. As dead cells reach the outermost layer, proteases called kallikreins¹¹ kallikreins
serine protease enzymes (KLK5, KLK7) that cleave the protein bridges holding corneocytes together, driving the orderly shedding of dead skin cells dissolve the protein links between them so they can shed naturally. The braking system for this process is a multi-domain protease inhibitor called LEKTI²² LEKTI
Lympho-Epithelial Kazal-Type Inhibitor, the protein encoded by SPINK5; contains 15 serine protease inhibitory domains and is expressed in skin, thymus, and mucous membranes, encoded by the SPINK5 gene. When LEKTI malfunctions, kallikrein proteases run unchecked — and the result is a compromised skin barrier, inflammation, and atopic disease.

The rs2303067 variant (c.1258A>G in coding notation; note that the GRCh38 plus-strand reference allele is A, which encodes Lys420, the risk form) introduces a single amino acid change in domain 6 of LEKTI: lysine at position 420 is replaced by glutamic acid (p.Lys420Glu). The G allele (Glu420) is actually the slightly more common and protective allele globally (about 52% by gnomAD v4); the A allele (Lys420) is the risk variant carried by approximately 48% of the global population. Carrying one or two copies of the A allele means your LEKTI protein is processed abnormally — with real consequences for skin barrier integrity and atopic disease risk.

The Mechanism

The Lys420 substitution (A allele) has been characterised at the molecular level by Fortugno et al. in a landmark 2012 functional study. The Lys residue at position 420 sits in the linker region between LEKTI inhibitory domains D6 and D7 — a region that is a substrate for furin, a cellular proprotein convertase³³ proprotein convertase
enzyme that cleaves precursor proteins at specific dibasic amino acid sequences, processing them into functional mature forms.

Normally, the LEKTI precursor is processed by furin into a series of overlapping inhibitory fragments. One of the most potent is the D6–D9 fragment, which has the strongest inhibitory activity against KLK5-mediated desmoglein-1 (DSG1) degradation⁴⁴ KLK5-mediated desmoglein-1 (DSG1) degradation
desmoglein-1 is a key structural protein of corneodesmosomes — the rivets holding skin cells together; when KLK5 cleaves it, desquamation proceeds; LEKTI fragment D6–D9 prevents this cleavage. The Lys420 substitution accelerates furin-mediated cleavage within the D6–D7 linker, destroying the D6–D9 fragment before it can form. The result is a functional LEKTI deficit: KLK5, KLK7, and elastase-2 are insufficiently inhibited, desmoglein-1 is over-cleaved, profilaggrin breakdown accelerates, and the skin barrier weakens. Compounding this, epidermis from Lys420/Lys420 donors shows elevated expression of TSLP⁵⁵ TSLP
thymic stromal lymphopoietin, a cytokine released by barrier- disrupted keratinocytes that drives Th2 immune skewing and atopic sensitisation, directly linking the structural barrier defect to atopic inflammation.

The Evidence

The clearest genetic signal for rs2303067 comes from disease-subtype analysis. A Slovenian case- control study by Dežman et al.⁶⁶ Dežman et al.
SPINK5 is associated with early-onset and CHI3L1 with late-onset atopic dermatitis. Int J Immunogenet, 2017 enrolled 241 atopic dermatitis patients and 164 healthy controls and found that rs2303067 was significantly associated specifically with early-onset AD (onset ≤8 years: OR=2.57, p=0.003). It was also associated with disease severity markers: hospitalization requirement (OR=2.76, p=0.006), disease duration ≥10 years (OR=2.32, p=0.008), and involvement of multiple body parts (OR=2.01, p=0.015).

The clinical significance is underscored by a 2023 case report from Moltrasio et al.⁷⁷ Moltrasio et al.
Netherton Syndrome Caused by Heterozygous Frameshift Mutation Combined with Homozygous c.1258A>G Polymorphism in SPINK5 Gene. Genes (Basel), 2023 describing a patient who developed Netherton syndrome with the combination of a heterozygous frameshift mutation AND homozygous rs2303067. The authors note that homozygous Lys420/Lys420 alone carries approximately 1.8× the population risk for atopic dermatitis, and when combined with a loss-of-function SPINK5 allele, produces haploinsufficiency sufficient for a full Netherton phenotype.

A large European population study by Weidinger et al.⁸⁸ Weidinger et al.
Analysis of SPINK5, KLK7, and FLG polymorphisms and eczema risk. J Allergy Clin Immunol, 2008 (2,774 cases, 10,607 controls) found a maternal transmission effect for rs2303067 but concluded it is not a major population-level eczema risk factor in unselected cohorts. This contrast with the Dežman study likely reflects phenotypic heterogeneity: the SPINK5 variant's effect is most pronounced in early-onset, barrier-driven atopic dermatitis — not in the broader, genetically heterogeneous eczema population. Studies of asthma alone have found no association, consistent with SPINK5's predominantly cutaneous and mucosal expression.

The Japanese population provided some of the earliest evidence. Kato et al.⁹⁹ Kato et al.
SPINK5 gene polymorphisms and atopic dermatitis in Japanese. Br J Dermatol, 2003 and Nishio et al.¹⁰¹⁰ Nishio et al.
SPINK5 polymorphisms and atopic dermatitis in Japanese. Genes Immun, 2003 both reported significant SPINK5–AD associations using transmission disequilibrium tests, establishing cross-ethnic consistency.

Practical Actions

The Lys420 allele's primary consequence is structural: impaired LEKTI activity leads to chronic subclinical protease hyperactivity in the skin, producing a leakier barrier and a lower threshold for atopic sensitisation. The actionable implications fall into three domains:

Barrier protection: Physical barrier support — particularly emollients that reduce transepidermal water loss — is specifically indicated by the mechanism, not as general skincare advice. Emollient therapy has clinical trial support for reducing AD incidence and severity, and the rationale is even stronger when LEKTI activity is constitutively reduced.

Trigger avoidance: A compromised LEKTI-mediated barrier admits allergens, irritants, and microbes more readily. This makes trigger identification — through specific IgE testing or patch testing — more productive than in barrier-intact individuals.

Monitoring for severe presentations: Homozygous Lys420 individuals (AA genotype) who also carry any second SPINK5 loss-of-function allele (rare, but present in the population) risk a Netherton-like phenotype. Severe early-onset ichthyosis, recurrent skin infections, and marked atopy in combination warrant SPINK5 gene sequencing.

Interactions

SPINK5 × FLG (filaggrin) variants: Weidinger et al. found no statistical interaction between rs2303067 and FLG loss-of-function variants (R501X, 2282del4) in their large European cohort, suggesting the two mechanisms — LEKTI impairment (protease pathway) and filaggrin loss (structural scaffold pathway) — act in parallel rather than synergistically. Carrying risk variants at both loci likely increases absolute AD risk additively. Related SPINK5 variants (rs2303065, rs2280099, rs8111930) have been examined in haplotype analyses; the Lys420Glu variant is generally the most functionally characterized within the SPINK5 locus.

SPINK5 × KLK5/KLK7 variants: Weidinger et al. also tested KLK7 (rs11567785) alongside SPINK5; neither showed interaction. The SPINK5/kallikrein axis is a candidate for compound effects, but published interaction data remain sparse.

The human cochlea relies on an extraordinary feat of ion management: within the spiral organ of Corti, potassium ions¹¹ potassium ions
K+; the primary charge carrier in cochlear mechanosensory transduction flow through hair cells during sound detection and must be continuously recycled through a network of gap junction channels before they can cause cellular toxicity. Connexin 26, encoded by GJB2²² Connexin 26, encoded by GJB2
Gap Junction Protein Beta-2; the most common cause of hereditary non-syndromic hearing loss worldwide is the principal protein of these recycling channels in the cochlear supporting cell network. The M34T variant (c.101T>C, p.Met34Thr, rs35887622) is a missense substitution in the first transmembrane domain of connexin 26 that substantially reduces channel conductance without eliminating it — creating a partial-loss-of-function allele that behaves quite differently from the severe truncating mutations that dominate the GJB2 literature.

Unlike c.35delG (rs80338939), which eliminates connexin 26 protein and causes severe-to-profound congenital deafness, M34T retains some channel activity. This subtlety has significant clinical consequences: homozygous M34T individuals typically have mild hearing loss (median pure-tone average ~30 dB), hearing loss may not be present at birth or may pass newborn screening, and onset often occurs in childhood or early adulthood. The result is a condition that is biologically meaningful but clinically easy to miss — and historically controversial because its high population frequency (approximately 1.5% carrier rate in Europeans) initially suggested it might be benign.

The Mechanism

M34T substitutes the nonpolar methionine at position 34 with the hydroxyl-bearing threonine, located within the first transmembrane helix (TM1) of connexin 26. This position is structurally critical: methionine 34 forms a hydrophobic contact with tryptophan 3³³ hydrophobic contact with tryptophan 3
W3; located in the N-terminal helix that lines the channel pore of the adjacent subunit. Molecular dynamics simulations show that the M34T substitution disrupts this hydrophobic interaction, altering the geometry of the pore funnel and causing the channel to reside primarily in a low-conductance state (approximately 13 picosiemens, versus ~120 pS for wild-type connexin 26 channels) — a roughly 90% reduction in single-channel conductance.

Importantly, M34T channels retain some residual activity rather than being completely non- functional. This distinguishes M34T from frameshift mutations and explains both the milder audiological phenotype and the reduced penetrance compared with loss-of-function alleles. Coexpression of wild-type and M34T connexin 26 in heterologous systems has also demonstrated a dominant-negative effect⁴⁴ dominant-negative effect
The mutant subunit incorporates into hexameric connexons alongside wild-type subunits, reducing the conductance of the entire channel complex, which may explain rare reports of apparent dominant inheritance in families. However, the weight of clinical and population evidence supports autosomal recessive inheritance as the operational mode in most cases.

The Evidence

The definitive classification of M34T as pathogenic came from the ClinGen Hearing Loss Variant Curation Expert Panel in 2019⁵⁵ ClinGen Hearing Loss Variant Curation Expert Panel in 2019
Shen et al., Genetics in Medicine; PMID 31160754, which reviewed functional, allelic, segregation, and population data for both M34T and the related V37I variant (rs72474224). The panel concluded that both variants are pathogenic for autosomal recessive nonsyndromic hearing loss with variable expressivity and incomplete penetrance. Despite the relatively high allele frequency in European populations (~1.5%), the evidence that M34T is significantly overrepresented in hearing loss cohorts compared to population controls outweighed the frequency concern.

Quantitative phenotyping data comes from a multicenter study of 1,531 biallelic GJB2 cases across 16 countries⁶⁶ multicenter study of 1,531 biallelic GJB2 cases across 16 countries
Snoeckx et al., PMID 16303844. M34T/M34T homozygotes had a median pure-tone average of 30 dB (mild hearing loss), while 35delG/M34T compound heterozygotes had a median of 34 dB. Both were among the three mildest genotype classes observed — far milder than the 35delG/35delG homozygotes, who had a median approaching severe-profound loss. A Polish cohort study⁷⁷ Polish cohort study
Pollak et al. 2007, PMID 17935238 estimated M34T penetrance at approximately 1/10 relative to mutations of undisputed pathogenicity, and documented significantly later onset and a progressive rather than congenital course for M34T-associated hearing loss.

The partial and progressive nature of M34T-related hearing loss means it often escapes newborn hearing screening. Standard otoacoustic emission and auditory brainstem response testing in neonates may classify an infant with biallelic M34T as "normal hearing," with measurable loss appearing only in mid-childhood or even adulthood.

Practical Implications

Biallelic M34T individuals (GG genotype) should have audiological evaluation regardless of whether they passed newborn hearing screening, since the mild loss may be subclinical at birth. Annual audiograms allow early detection of progression before communication is affected. When hearing aid candidacy is reached (typically when thresholds in the speech frequencies average 25 dB or more), early fitting prevents the cognitive burden of straining to hear in noise. The audiogram shape is typically flat or mildly downsloping, a profile that responds very well to modern digital amplification.

Noise avoidance is particularly important: cochlear K+ recycling in biallelic M34T carriers has less reserve capacity, and animal and clinical data suggest that noise-induced hearing loss and ototoxic drug effects may be amplified in GJB2-related hearing impairment. Loud occupational or recreational noise (>85 dB time-weighted average) and ototoxic antibiotics such as aminoglycosides deserve special attention.

Single heterozygous carriers (AG genotype) have normal hearing. Their significance is reproductive: one in ~35 Europeans carries a GJB2 pathogenic variant, and partner carrier testing before pregnancy can identify couples at 25% risk per pregnancy of having a biallelic child with hearing loss.

Interactions

M34T produces compound heterozygous hearing loss when inherited alongside other pathogenic GJB2 alleles on the opposite chromosome. The most common combination in European populations is M34T/35delG (rs80338939): compound heterozygotes have a median threshold around 34 dB, milder than 35delG homozygotes but generally worse than M34T homozygotes. Compound M34T heterozygosity with the Asian-dominant c.235delC allele or the Ashkenazi 167delT (rs80338942) also produces mild-to-moderate hearing loss. The clinical rule in DFNB1-spectrum hearing loss is that severity correlates with the less severe of the two alleles — since M34T is a partial loss-of-function allele, it "protects" compound heterozygotes from the severe phenotype associated with the co-inherited truncating allele.

Large deletions in the neighbouring GJB6 gene⁸⁸ neighbouring GJB6 gene
Encodes connexin 30, which forms heteromeric gap junctions with connexin 26 in cochlear supporting cells — particularly del(GJB6-D13S1830) — can also serve as a second allele in trans with M34T. A single GJB2 M34T allele in a deaf individual with no apparent second GJB2 variant should prompt testing for GJB6 regulatory deletions.

SLC19A1 (Solute Carrier Family 19 Member 1), also known as the reduced folate carrier (RFC1), is the primary transporter that moves folate and antifolate drugs from the bloodstream into cells. The well-characterized G80A variant rs1051266¹¹ rs1051266
The missense SLC19A1 variant most extensively studied for folate transport and methotrexate pharmacogenomics sits in the transmembrane domain and directly affects transporter function. rs3788205 is a separate intronic variant in the same gene — it does not alter the protein itself, but it tags broader genetic variation across the SLC19A1 locus through linkage with adjacent functional variants.

The Mechanism

As an intronic variant, rs3788205 does not directly change the SLC19A1 amino acid sequence. Intronic variants can theoretically influence gene expression through effects on splicing enhancers, regulatory elements, or transcription factor binding sites embedded within introns. However, no functional characterization of this specific site has been published to date. The variant's appearance across multiple folate-pathway disease studies most likely reflects linkage disequilibrium ²² Linkage disequilibrium (LD): nearby variants on the same chromosome are inherited together, so one can be a statistical proxy for another without directly causing any effect with rs1051266 or other functional SLC19A1 variants. The T allele is the minor allele globally (~28% overall, ~30% in Europeans, only ~7% in Africans per dbSNP ALFA data), making it an informative population marker for SLC19A1 haplotype structure.

The Evidence

The clearest direct finding comes from a Phase III lung cancer trial³³ Phase III lung cancer trial
Smit EF et al. Biomarker analysis of pemetrexed-carboplatin vs. etoposide-carboplatin in SCLC. Annals of Oncology, 2012, which found that rs3788205 interacted with gamma-glutamyl hydrolase (GGH)-associated SNPs to predict overall survival in patients receiving pemetrexed-carboplatin. This is biologically plausible since pemetrexed, like methotrexate, depends on RFC1/SLC19A1 for cellular entry. An Italian case-control study⁴⁴ Italian case-control study
Girardi A et al. RFC1 and non-syndromic cleft lip/palate association study in Italy. J Craniomaxillofac Surg, 2014 examined rs3788205 alongside rs1051266 and rs4818789 in the context of cleft lip with or without cleft palate, reporting weak association signals across the three RFC1 polymorphisms. A Japanese autism spectrum disorder study⁵⁵ Japanese autism spectrum disorder study
Mahmuda NA et al. SLC19A1/RFC1 SNPs in autism spectrum disorder. Int J Mol Sci, 2016 included rs3788205 in a 13-SNP SLC19A1 panel but found no significant association after correction for multiple testing. rs3788205 is not among the five SLC19A1 tagSNPs that reached corrected significance in the colorectal adenoma study Levine AJ et al., 2011⁶⁶ Levine AJ et al., 2011
Cancer Causes Control, folate pathway variation and distal colorectal adenoma.

Taken together, the evidence for this variant as an independent risk factor is weak. The evidence level is emerging — the variant appears across folate-pathway studies but has not been replicated with a clear, directional effect in any single phenotype.

Practical Context

If you carry the minor T allele — particularly as a TT homozygote — your result reflects a less common SLC19A1 haplotype that co-occurs with other folate pathway variants in studies examining anti-folate drug response, birth defects, and gastrointestinal cancer risk. The practical implications are best understood in the context of your other folate pathway results, especially rs1051266 (the G80A missense variant in the same gene) and MTHFR variants.

The most actionable approach for anyone with T-allele status at this locus is to ensure optimal folate intake and to use methylfolate rather than synthetic folic acid — advice consistent with the broader SLC19A1 pathway evidence.

Interactions

rs3788205 is in the same gene as rs1051266 (G80A, His27Arg), the primary functional variant in SLC19A1. Compound haplotypes across these two sites define distinct SLC19A1 genetic backgrounds. Studies of methotrexate toxicity use haplotype-based approaches encompassing both variants alongside rs7499 and rs2838956. If you carry the G80A T allele at rs1051266 in addition to the minor T allele here, you may be on a specific SLC19A1 haplotype associated with altered folate transporter behavior.

CYP2D6 is one of the most clinically significant drug-metabolizing enzymes in the human body. Despite making up only about 2% of liver CYP450 content, it metabolizes approximately 25% of all clinically used medications. The *4 allele¹¹ rs3892097 is the most common non-functional variant in European populations, carried by about 25% of people.

The Mechanism

The CYP2D6*4 variant is a splice site mutation²² A splice site mutation disrupts the boundary between coding and non-coding DNA, preventing correct protein assembly³³ C>T on the plus strand (historically called G1846A on the coding strand) at the intron 3/exon 4 boundary that causes aberrant mRNA splicing, producing a completely non-functional enzyme. Unlike variants that merely reduce activity, *4 abolishes CYP2D6 function entirely from that allele. Individuals homozygous for *4 (TT) are classified as CYP2D6 poor metabolizers.

Prodrugs vs. Active Drugs

The clinical impact of CYP2D6 status depends on whether a medication is a prodrug⁴⁴ A prodrug is inactive until the body converts it to its active form or an active drug (needs CYP2D6 to be eliminated).

For prodrugs like codeine and tramadol, poor metabolizers get NO pain relief because these drugs cannot be converted to their active forms⁵⁵ Codeine is converted to morphine; tramadol to O-desmethyltramadol. This is not a matter of dose adjustment - these drugs simply will not work.

For active drugs like many antidepressants⁶⁶ e.g. fluoxetine, paroxetine, venlafaxine, beta-blockers, and tamoxifen, poor metabolizers accumulate higher drug levels, increasing the risk of side effects and toxicity.

The Evidence

CYP2D6 pharmacogenomics has the strongest evidence base of any pharmacogene. The Clinical Pharmacogenetics Implementation Consortium (CPIC)⁷⁷ Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)⁸⁸ Dutch Pharmacogenetics Working Group (DPWG)
Dutch Pharmacogenetics Working Group at PharmGKB have published dosing guidelines for over 30 CYP2D6 substrate medications. Major medical centers now routinely test CYP2D6 before prescribing certain medications. The Gaedigk activity score system⁹⁹ Gaedigk activity score system
Gaedigk A et al. The CYP2D6 activity score. Clin Pharmacol Ther, 2008 translates complex CYP2D6 genotypes into a quantitative measure of predicted enzyme activity, enabling standardized phenotype assignment.

What You Should Do

If you carry even one *4 allele, this is clinically actionable information. Share your CYP2D6 status with all prescribing physicians and pharmacists. Consider requesting your full CYP2D6 genotype through clinical pharmacogenomic testing, as 23andMe only captures some of the known variants.

Most people know that DNA variants in protein-coding regions can alter how enzymes and channels work. But rs5210 tells a more subtle story. This variant sits in the 3' untranslated region (3' UTR) of KCNJ11 — the gene encoding Kir6.2, the pore-forming subunit of the ATP-sensitive potassium (KATP) channel¹¹ ATP-sensitive potassium (KATP) channel
The KATP channel in pancreatic beta cells links glucose metabolism to insulin secretion. When glucose rises, ATP builds up, closes the channel, depolarizes the cell, and triggers insulin release. Unlike the neighboring rs5219 (E23K) missense variant, rs5210 doesn't change the Kir6.2 protein sequence at all — instead, it appears to influence how much of the protein gets made.

rs5210 is co-listed with rs5219 as a KCNJ11 co-variant, and the two SNPs are in moderate linkage disequilibrium in most populations. However, rs5210 has independent associations with both type 2 diabetes risk and sulfonylurea drug response, making it worth profiling on its own merits.

The Mechanism

The rs5210 variant lies within a conserved region of the KCNJ11 3' UTR. A meta-analysis²² A meta-analysis
Qin LJ et al. Meta-analysis of association of common variants in the KCNJ11-ABCC8 region with type 2 diabetes. Genet Mol Res, 2013 proposed that the risk allele (G) maintains a binding site for the microRNA hsa-miR-1910, while the A allele disrupts this binding site. MicroRNAs binding to the 3' UTR typically suppress gene expression by destabilizing mRNA or blocking translation³³ destabilizing mRNA or blocking translation
miRNA-3'UTR interactions are a major post-transcriptional regulatory mechanism controlling protein abundance. If the G allele retains miR-1910 binding, this could reduce KCNJ11 expression and lower Kir6.2 protein levels, leading to reduced KATP channel density in beta-cell membranes. Fewer functional channels could subtly impair the glucose-sensing mechanism.

This mechanism remains proposed rather than fully validated — the functional studies needed to confirm miR-1910 regulation of KCNJ11 in human beta cells have not yet been published. The 3' UTR location and the observed T2D association are consistent with the model, but the molecular details are still emerging.

The Evidence

The key meta-analysis⁴⁴ meta-analysis
Qin LJ et al. Genet Mol Res, 2013 analyzed 41 case-control studies encompassing 61,879 subjects across multiple populations. The rs5210 G allele showed an allelic odds ratio of 1.16 (95% CI: 1.08–1.24; P = 0.023) for type 2 diabetes — a modest but statistically robust association. For context, this effect size is comparable to the well-established rs5219 E23K variant (~OR 1.12 per allele), which has been studied far more extensively.

Beyond diabetes risk, rs5210 appears to affect drug response. In a study of T2D patients, rs5210 was associated with improved clinical efficacy of gliclazide⁵⁵ rs5210 was associated with improved clinical efficacy of gliclazide
Wang Y et al. Correlation between KCNJ11 gene polymorphisms, type 2 and post-transplant diabetes mellitus in Asian Indian population. Genes Dis, 2015, a sulfonylurea that works by binding to the SUR1 subunit and closing the KATP channel. A separate cohort study found rs5210 associated with improved fasting plasma glucose response to treatment⁶⁶ rs5210 associated with improved fasting plasma glucose response to treatment
Gloyn AL et al., 2009.

An Indian population study found rs5210 associated with T2D under a dominant model (OR 2.07, 95% CI 1.30–3.27; P = 0.001), with larger effect sizes than seen in European populations — a pattern also observed for the related rs5219 variant. The variant showed positive association with gestational diabetes and OGTT values⁷⁷ positive association with gestational diabetes and OGTT values
Gaston J et al. Indian pregnant women study, 2018 in Indian women as well.

Not all studies agree: one Iranian study found no significant association in 111 T2D cases vs 82 controls (PMID 33853507), and a 2024 GDM meta-analysis covering 3 studies found no association with gestational diabetes (PMID 38932913). The overall evidence supports a real but modest effect, with possible population heterogeneity.

Practical Actions

The clinical takeaway from rs5210 runs parallel to, but is independent of, the better-known rs5219 variant. Carriers of the G allele (the majority of people) have a mildly elevated risk of type 2 diabetes, expressed additively — two G alleles confer modestly more risk than one. The A allele is the protective minority genotype.

For sulfonylurea-treated diabetes, rs5210 G allele carriers may show better response to gliclazide specifically, and possibly to the sulfonylurea class broadly — this variant is one element of the pharmacogenomic picture your doctor can consider when calibrating doses.

Magnesium and chromium support insulin production and signaling — they are particularly relevant when beta-cell KATP channel function is subtly impaired.

Interactions

rs5210 sits approximately 1,300 bp upstream of rs5219 (E23K) in the KCNJ11 gene. The two variants are in partial linkage disequilibrium and may act in combination on KATP channel function — rs5219 at the protein level, rs5210 at the expression level. Studies examining the KCNJ11-ABCC8 region as a haplotype block consistently find both variants independently contribute to T2D and sulfonylurea pharmacogenomics.

The ABCC8 rs757110 (Ser1369Ala) variant encodes the SUR1 subunit — the other half of the KATP channel complex. ABCC8 and KCNJ11 variants together form the complete pharmacogenomic picture for sulfonylurea response. Carrying risk alleles at rs5210, rs5219, and rs757110 simultaneously is expected to compound the effect on insulin secretion, though dedicated multi-variant analysis of this specific combination is limited.